The foundation of everything we do at Yazen
At Yazen, we don’t follow trends – we follow science. Our entire approach to weight care is grounded in decades of medical research, modern clinical evidence, and real-world outcomes, built on long-term results from a steadily increasing patient base. Every treatment, every recommendation, and every support tool is backed by data – not hype.
We believe sustainable weight loss is not about willpower or one-size-fits-all solutions. It’s about understanding the biology of obesity, personalising medical care, and supporting long-term behavioural change through scientifically proven methods.
.webp)
Why science matters
Obesity is a chronic, relapsing disease that presents a serious risk to health. Obesity requires long-term management and follow-up, and not a lifestyle choice. That’s why our model combines the latest generation of weight loss medications (like GLP-1 and GLP-1/GIP receptor agonists), personalised dosing, ongoing medical supervision, and lifestyle coaching. It’s a method that works – and we have the numbers to prove it.
Read more about the science behind our programme
If you want to understand how the Yazen Model is transforming obesity treatment across Europe, we recommend diving into our articles. Discover how digital tools can improve medication adherence, how personalised care impacts long-term weight outcomes, and why medical treatment needs to be part of the conversation.
.webp)
Sustainable Weight Loss and Health Benefits in Obesity Care: 18-Month Real-World-Evaluation Results in a Virtual Care Setting from Yazens First Operational Quality follow-up
This 18-month real-world evaluation data analysis demonstrates that Yazen Health’s fully digital care model, integrating pharmacological treatment and lifestyle intervention can provide effective, sustainable results in a real-world setting.
Summary
Patients achieved a weight reduction of 16.6%, accompanied by improvements in metabolic health markers including laboratory values, despite medication supply limitations and without using the maximum recommended dose of semaglutide. 70% remained in the program after 12 months. Weight loss outcomes were comparable to those observed in RCTs such as the STEP trials1-2.
.webp)
High Adherence to GLP-1 Receptor Agonists: 18-Month Outcomes from the Yazen Model
High adherence rates to GLP-1 receptor agonists within a structured, digitally based weight management programme, may contribute to improved long-term medication adherence.
Summary
This real-world analysis from Yazens first large scale operational quality follow-up, demonstrates almost 70% compliance with GLP-1 medications at 12 months, surpassing earlier studies that showed 20-50%1-4. After 2 years*, 60% of patients were still in treatment.
.webp)
The Yazen Model - Modern Obesity Treatment Given Via a Digital Care Model. A Descriptive Analysis
The Yazen Model enables modern obesity treatment, integrating medical treatment, lifestyle intervention and social support. By now*, more than 30,000 patients have received treatment using this model.
Summary
The Yazen Model goes beyond traditional methods, providing patients with the tools to manage their disease, addressing medical and behavioural aspects, education and social support via a digital platform for accessible, continuous and effective weight loss and management.
New research: over a third of Brits see obesity as a personal choice
A new survey by Yazen Health uncovers widespread misconceptions about obesity, with over one-third of Brits seeing it as a personal choice rather than a chronic disease. These findings highlight the urgent need for greater public education and medically-guided obesity care.
